New combo therapy tested to stop aggressive uterine cancer from returning
NCT ID NCT03932409
Summary
This study is testing a new treatment plan for people with a high risk of their endometrial (uterine) cancer coming back after surgery. It combines a short course of targeted radiation with an immunotherapy drug (pembrolizumab) and then adds chemotherapy. The main goal is to see if this three-part approach is safe and practical for patients to complete.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
LSU Health New Orleans
New Orleans, Louisiana, 70112, United States
-
Stephenson Cancer Center
Oklahoma City, Oklahoma, 73104, United States
Conditions
Explore the condition pages connected to this study.